about
Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoidsRelevance of tumor-infiltrating lymphocytes in breast cancerImmune modulation of the tumor microenvironment for enhancing cancer immunotherapyRoutes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in miceFrizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growthExpression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic MiceEmbryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in miceFoxp3 expression in macrophages associated with RENCA tumors in mice.Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyEngineering T cell function using chimeric antigen receptors identified using a DNA library approachTherapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.The potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy.Cross-talk between tumors can affect responses to therapyGene modification strategies to induce tumor immunity.CD73: A potential biomarker for anti-PD-1 therapyCAR-T cells are serial killersSupernatural T cells: genetic modification of T cells for cancer therapy.The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene.Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceVirotherapy, gene transfer and immunostimulatory monoclonal antibodies.RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsCD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerBlockade of A2A receptors potently suppresses the metastasis of CD73+ tumorsImmunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaA role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.Environmental enrichment does not impact on tumor growth in mice.A2A blockade enhances anti-metastatic immune responses.Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.Enhancing adoptive immunotherapy of cancer.Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapyActivating and inhibitory receptors of natural killer cells.Genetic modification of natural killer cells for adoptive cellular immunotherapy.Alloreactive natural killer cells in hematopoietic stem cell transplantation.
P50
Q24305464-947F9D3D-F016-407F-80D3-6663EE0A5A19Q26795598-88926272-DFC6-49D7-9776-C404BA792B34Q27002646-984E4AA7-36AE-44EF-8C98-857D8C0C1811Q27335400-C7B0DCB8-9F9D-42CA-A358-773B55CE6B6BQ28251458-FE77C99A-F21C-4896-BF2B-FE6DD2C26B75Q30399332-55149AEE-312F-484A-8ED6-196C6CC7B5ABQ30403182-52496D4C-6867-41CE-806C-8E3589048295Q33863928-82A4BBA5-6C76-43D0-B359-87F6AA39E3A1Q34048020-975FAB6C-9AAB-49B2-B125-78125EBB8FE0Q34244875-1093BAF8-C30F-499A-859F-11AA207EC2F3Q34271151-0A17E05C-780F-494F-907F-4258D5A8AABAQ34374036-AB53E89C-FB06-4C12-9705-B8BABCA21EB4Q34550649-55C84204-6558-493E-A787-C36970B0DF6BQ34717977-69789ECD-8401-4A35-B8AE-82BB345C38E1Q35053658-158AD8D3-2986-40A8-959F-86845121C272Q35201835-83C91CBB-3A90-4B38-803A-8DA1438CFBC9Q35547103-7FC83964-4E51-467F-BEA5-CF11BE0C62BCQ35799079-97AB786F-9838-4CD0-BC82-C85C42952CCAQ36104197-166C1E65-4831-47C5-B048-D64FCCE72B83Q36107945-67E939BB-529B-4602-A310-564B00DFA07AQ36256299-DA9D5CDA-016D-493E-962C-FC5FA1E16141Q36328805-B217279C-D556-4DA0-8F6F-1BDE40B89B84Q36399692-DC04FADD-B71D-4FD2-9770-9F3654B701A6Q36403509-31651EFD-2868-4200-BE9B-8C9ACC5B797CQ36456487-9CE69C49-D04E-4257-A938-C6341AB2E9B6Q36693087-4061540B-7A3A-4EF1-BA8B-8DDD6A2BD189Q36991010-B1578927-53FB-43EA-BB8A-66BB54396ABEQ37157425-B244E829-394C-45A0-A71C-BC24ED3DCE28Q37222191-6540FFDA-F9A1-41AA-ACF2-F6D459281EDBQ37224591-AA6B5564-59B0-4307-BA61-CE40ABDF094EQ37316845-C21E55E3-BEBE-4696-B18E-D0FB9E8664F5Q37376346-7D0B3997-CB70-453D-865B-6F9888615665Q37482972-05BD337F-A40E-4C9B-B094-6BF33DEB31A9Q37589208-B979315C-FCFF-4714-92D4-E96882666F2AQ37602251-603AC063-65FC-4A70-8D52-0406BC509191Q37687429-C5AC09EB-7C55-4241-9297-0C587A6EC277Q37690485-63945B0A-09ED-4A6C-88D4-42DDB47DDD36Q37766751-56CB8AEA-84F0-4D24-821F-21C147772060Q37773285-6EEA437E-147F-422F-AE06-BC2727E99115Q37780850-BD4C2DE5-7F02-4AC2-9BDE-E8DB973CD5D7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Phillip K. Darcy
@ast
Phillip K. Darcy
@en
Phillip K. Darcy
@es
Phillip K. Darcy
@nl
Phillip K. Darcy
@sl
type
label
Phillip K. Darcy
@ast
Phillip K. Darcy
@en
Phillip K. Darcy
@es
Phillip K. Darcy
@nl
Phillip K. Darcy
@sl
prefLabel
Phillip K. Darcy
@ast
Phillip K. Darcy
@en
Phillip K. Darcy
@es
Phillip K. Darcy
@nl
Phillip K. Darcy
@sl
P106
P1153
7006577808
P2038
Phillip_Darcy
P21
P31
P496
0000-0002-5303-9561